Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)
Background: The mass vaccination campaign against SARS-CoV-2 was started in Tunisia on 13 March 2021 by using progressively seven different vaccines approved for emergency use. Herein, we aimed to evaluate the humoral and cellular immunity in subjects aged 40 years and over who received one of the f...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1189 |
| _version_ | 1797407557682200576 |
|---|---|
| author | Melika Ben Ahmed Hedia Bellali Mariem Gdoura Imen Zamali Ouafa Kallala Ahlem Ben Hmid Walid Hamdi Hela Ayari Hajer Fares Karim Mechri Soumaya Marzouki Henda Triki Nissaf Ben Alaya Mohamed Kouni Chahed Anis Klouz Sonia Sebai Ben Amor Chiheb Ben Rayana Myriam Razgallah Khrouf Chokri Hamouda Noomene Elkadri Riadh Daghfous Abdelhalim Trabelsi |
| author_facet | Melika Ben Ahmed Hedia Bellali Mariem Gdoura Imen Zamali Ouafa Kallala Ahlem Ben Hmid Walid Hamdi Hela Ayari Hajer Fares Karim Mechri Soumaya Marzouki Henda Triki Nissaf Ben Alaya Mohamed Kouni Chahed Anis Klouz Sonia Sebai Ben Amor Chiheb Ben Rayana Myriam Razgallah Khrouf Chokri Hamouda Noomene Elkadri Riadh Daghfous Abdelhalim Trabelsi |
| author_sort | Melika Ben Ahmed |
| collection | DOAJ |
| description | Background: The mass vaccination campaign against SARS-CoV-2 was started in Tunisia on 13 March 2021 by using progressively seven different vaccines approved for emergency use. Herein, we aimed to evaluate the humoral and cellular immunity in subjects aged 40 years and over who received one of the following two-dose regimen vaccines against SARS-CoV-2, namely mRNA-1273 or Spikevax (Moderna), BNT162B2 or Comirnaty (Pfizer-BioNTech), Gam-COVID-Vac or Sputnik V (Gamaleya Research Institute), ChAdOx1-S or Vaxzevria (AstraZeneca), BIBP (Sinopharm), and Coronavac (Sinovac). Material and methods: For each type of vaccine, a sample of subjects aged 40 and over was randomly selected from the national platform for monitoring COVID-19 vaccination and contacted to participate to this study. All consenting participants were sampled for peripheral blood at 3–7 weeks after the second vaccine dose to perform anti-S and anti-N serology by the Elecsys<sup>®</sup> (Lenexa, KS, USA) anti-SARS-CoV-2 assays (Roche<sup>®</sup> Basel, Switzerland). The CD4 and CD8 T cell responses were evaluated by the QuantiFERON<sup>®</sup> SARS-CoV-2 (Qiagen<sup>®</sup> Basel, Switzerland) for a randomly selected sub-group. Results: A total of 501 people consented to the study and, of them, 133 were included for the cellular response investigations. Both humoral and cellular immune responses against SARS-CoV-2 antigens differed significantly between all tested groups. RNA vaccines induced the highest levels of humoral and cellular anti-S responses followed by adenovirus vaccines and then by inactivated vaccines. Vaccines from the same platform induced similar levels of specific anti-S immune responses except in the case of the Sputnik V and the AstraZeneca vaccine, which exhibited contrasting effects on humoral and cellular responses. When analyses were performed in subjects with negative anti-N antibodies, results were similar to those obtained within the total cohort, except for the Moderna vaccine, which gave a better cellular immune response than the Pfizer vaccine and RNA vaccines, which induced similar cellular immune responses to those of adenovirus vaccines. Conclusion: Collectively, our data confirmed the superiority of the RNA-based COVID-19 vaccines, in particular that of Moderna, for both humoral and cellular immunogenicity. Our results comparing between different vaccine platforms in a similar population are of great importance since they may help decision makers to adopt the best strategy for further national vaccination programs. |
| first_indexed | 2024-03-09T03:43:17Z |
| format | Article |
| id | doaj.art-42355f1350884b43bd3914750c185fcf |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:43:17Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-42355f1350884b43bd3914750c185fcf2023-12-03T14:36:31ZengMDPI AGVaccines2076-393X2022-07-01108118910.3390/vaccines10081189Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)Melika Ben Ahmed0Hedia Bellali1Mariem Gdoura2Imen Zamali3Ouafa Kallala4Ahlem Ben Hmid5Walid Hamdi6Hela Ayari7Hajer Fares8Karim Mechri9Soumaya Marzouki10Henda Triki11Nissaf Ben Alaya12Mohamed Kouni Chahed13Anis Klouz14Sonia Sebai Ben Amor15Chiheb Ben Rayana16Myriam Razgallah Khrouf17Chokri Hamouda18Noomene Elkadri19Riadh Daghfous20Abdelhalim Trabelsi21Laboratory of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaLaboratory of Virology, Pasteur Institute of Tunis, Tunis 1002, TunisiaLaboratory of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, TunisiaFaculty of Pharmacy, University of Monastir, Monastir 5000, TunisiaLaboratory of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, TunisiaLaboratory of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, TunisiaFaculty of Pharmacy, University of Monastir, Monastir 5000, TunisiaFaculty of Pharmacy, University of Monastir, Monastir 5000, TunisiaLaboratory of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, TunisiaLaboratory of Clinical Immunology, Pasteur Institute of Tunis, Tunis 1002, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaNational Drug Control Laboratory, Tunis 1082, TunisiaFaculty of Pharmacy, University of Monastir, Monastir 5000, TunisiaFaculty of Pharmacy, University of Monastir, Monastir 5000, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaFaculty of Medicine of Tunis, Tunis El Manar University, Tunis 1068, TunisiaFaculty of Pharmacy, University of Monastir, Monastir 5000, TunisiaBackground: The mass vaccination campaign against SARS-CoV-2 was started in Tunisia on 13 March 2021 by using progressively seven different vaccines approved for emergency use. Herein, we aimed to evaluate the humoral and cellular immunity in subjects aged 40 years and over who received one of the following two-dose regimen vaccines against SARS-CoV-2, namely mRNA-1273 or Spikevax (Moderna), BNT162B2 or Comirnaty (Pfizer-BioNTech), Gam-COVID-Vac or Sputnik V (Gamaleya Research Institute), ChAdOx1-S or Vaxzevria (AstraZeneca), BIBP (Sinopharm), and Coronavac (Sinovac). Material and methods: For each type of vaccine, a sample of subjects aged 40 and over was randomly selected from the national platform for monitoring COVID-19 vaccination and contacted to participate to this study. All consenting participants were sampled for peripheral blood at 3–7 weeks after the second vaccine dose to perform anti-S and anti-N serology by the Elecsys<sup>®</sup> (Lenexa, KS, USA) anti-SARS-CoV-2 assays (Roche<sup>®</sup> Basel, Switzerland). The CD4 and CD8 T cell responses were evaluated by the QuantiFERON<sup>®</sup> SARS-CoV-2 (Qiagen<sup>®</sup> Basel, Switzerland) for a randomly selected sub-group. Results: A total of 501 people consented to the study and, of them, 133 were included for the cellular response investigations. Both humoral and cellular immune responses against SARS-CoV-2 antigens differed significantly between all tested groups. RNA vaccines induced the highest levels of humoral and cellular anti-S responses followed by adenovirus vaccines and then by inactivated vaccines. Vaccines from the same platform induced similar levels of specific anti-S immune responses except in the case of the Sputnik V and the AstraZeneca vaccine, which exhibited contrasting effects on humoral and cellular responses. When analyses were performed in subjects with negative anti-N antibodies, results were similar to those obtained within the total cohort, except for the Moderna vaccine, which gave a better cellular immune response than the Pfizer vaccine and RNA vaccines, which induced similar cellular immune responses to those of adenovirus vaccines. Conclusion: Collectively, our data confirmed the superiority of the RNA-based COVID-19 vaccines, in particular that of Moderna, for both humoral and cellular immunogenicity. Our results comparing between different vaccine platforms in a similar population are of great importance since they may help decision makers to adopt the best strategy for further national vaccination programs.https://www.mdpi.com/2076-393X/10/8/1189COVID-19vaccineshumoral immunitycellular immunity |
| spellingShingle | Melika Ben Ahmed Hedia Bellali Mariem Gdoura Imen Zamali Ouafa Kallala Ahlem Ben Hmid Walid Hamdi Hela Ayari Hajer Fares Karim Mechri Soumaya Marzouki Henda Triki Nissaf Ben Alaya Mohamed Kouni Chahed Anis Klouz Sonia Sebai Ben Amor Chiheb Ben Rayana Myriam Razgallah Khrouf Chokri Hamouda Noomene Elkadri Riadh Daghfous Abdelhalim Trabelsi Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa) Vaccines COVID-19 vaccines humoral immunity cellular immunity |
| title | Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa) |
| title_full | Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa) |
| title_fullStr | Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa) |
| title_full_unstemmed | Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa) |
| title_short | Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa) |
| title_sort | humoral and cellular immunogenicity of six different vaccines against sars cov 2 in adults a comparative study in tunisia north africa |
| topic | COVID-19 vaccines humoral immunity cellular immunity |
| url | https://www.mdpi.com/2076-393X/10/8/1189 |
| work_keys_str_mv | AT melikabenahmed humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT hediabellali humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT mariemgdoura humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT imenzamali humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT ouafakallala humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT ahlembenhmid humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT walidhamdi humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT helaayari humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT hajerfares humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT karimmechri humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT soumayamarzouki humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT hendatriki humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT nissafbenalaya humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT mohamedkounichahed humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT anisklouz humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT soniasebaibenamor humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT chihebbenrayana humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT myriamrazgallahkhrouf humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT chokrihamouda humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT noomeneelkadri humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT riadhdaghfous humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica AT abdelhalimtrabelsi humoralandcellularimmunogenicityofsixdifferentvaccinesagainstsarscov2inadultsacomparativestudyintunisianorthafrica |